Roden — November 20, 2020 — PureIMS, a clinical stage pharmaceutical and medication systems company focused on developing and commercializing innovative inhaled therapies for systemic and respiratory diseases has appointed Bram van Dijck to the role of Chief Executive Officer (CEO) with immediate effect.
Mr. van Dijck joins PureIMS from the Grünenthal Group where he was Global Head Portfolio Management. He brings over 30 years of experience in commercial, business development and general management gained from senior functions at Cipla, Hospira, Teva Pharmaceuticals, Organon and Abbott Laboratories.
He successfully led multiple medical device product launches and was responsible for their operations and marketing & sales. Apart from medical devices, Mr. van Dijck’s expertise covers a wide range of therapeutic areas in pharmaceuticals. As a general manager he managed cross-functional teams, set up new global and European business units and restructured existing ones.
Mr. van Dijck’s appointment to the leadership team coincides with PureIMS transitioning from an academic spin-off to a mature pharmaceutical company focusing on the final development of its clinical-stage lead programs Levodopa Cyclops™ and Epinephrine Cyclops™. He succeeds Dr. Reinier Schwietert whose responsibilities within the leadership team will concentrate on the scientific and medical strategies.
Mr. Robert Polano, partner at Carduso Capital said: “On behalf of the PureIMS investors I am pleased to welcome Bram to the PureIMS leadership. We have great confidence in his capacities that will be critically important at a time where the company aims to raise new funding and, either itself or through a partnership, bring its lead programs to the stage of marketing authorization. Bram’s broad expertise with medical devices and pharmaceuticals, combined with his senior leadership experience, makes him the ideal candidate to lead the company to successfully realizing these new ambitions.”
Commenting on his appointment Mr. van Dijck mentioned: “I am thrilled to join PureIMS at a stage where my specific expertise will be complementary to the knowledge of the existing team. I look forward to working with the highly motivated PureIMS crew and to leading the company through its next phase towards commercialization.
Mr. van Dijck studied economics and foreign languages at the International School of Business Management, and obtained an MBA from INSEAD Fontainebleau, France.
PureIMS is a clinical-stage pharmaceutical and medication systems company focused on developing and commercializing innovative inhaled therapies for the treatment of systemic and respiratory diseases with significant unmet medical needs. Cyclops™ is an easy-to-use, pre-filled, disposable dry powder inhaler (DPI) that is developed for inhalation powders and can be produced in a cost-effective way because of its simple yet sophisticated proprietary design. Upon inhalation it uses the patient’s breath to disperse the dry powder formulation into small particles appropriately sized for deep lung deposition. Cyclops™ has several advantages compared to standard-of-care DPIs across key therapeutic areas. These attributes enable the hygienic and effective use on a worldwide scale. PureIMS’ lead candidates, Levodopa Cyclops™ and Epinephrine Cyclops™, are in the final development stage as rescue therapies for OFF-episodes in Parkinson’s disease and allergy induced anaphylaxis, respectively. One product, Colistin Cyclops™, is already marketed and reimbursed under a compassionate use regimen for the treatment of cystic fibrosis patients. PureIMS recently conducted an open-label Phase I clinical trial with promising results for Hydroxychloroquine Cyclops™ for intervention in SARS-CoV-2 and possible future coronavirus outbreaks.
For more information, press and investors only:
Bram van Dijck
For more information on Company: